These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9838354)

  • 21. Losartan and renal transplantation.
    Aurup P; Smith RD
    Lancet; 1998 Mar; 351(9107):990. PubMed ID: 9734972
    [No Abstract]   [Full Text] [Related]  

  • 22. Losartan for therapy of posttransplant erythrocytosis.
    Navarro JF; Macía M; García J
    Clin Nephrol; 1997 Nov; 48(5):335. PubMed ID: 9403221
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of posttransplant erythrocytosis with losartan.
    Ducloux D; Fournier V; Bresson-Vautrin C; Chalopin JM
    Transplant Proc; 1997 Aug; 29(5):2407-8. PubMed ID: 9270784
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy of enalapril in the treatment of erythrocytosis in patients with renal allografts.
    Carvalho MF; Balbi AL; Corrêa LA; Soares VA
    Transplant Proc; 1996 Dec; 28(6):3377. PubMed ID: 8962316
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure.
    Mora-Macía J; Cases A; Calero F; Barceló P
    Nephrol Dial Transplant; 2001; 16 Suppl 1():82-4. PubMed ID: 11369829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of enalapril and losartan in the treatment of posttransplant erythrocytosis.
    Celik A; Ok E; Unsal A; Töz H; Atabay G
    Nephron; 2000 Nov; 86(3):394-5. PubMed ID: 11096321
    [No Abstract]   [Full Text] [Related]  

  • 27. Expression of angiotensin II type I receptor on erythroid progenitors of patients with post transplant erythrocytosis.
    Gupta M; Miller BA; Ahsan N; Ulsh PJ; Zhang MY; Cheung JY; Yang HC
    Transplantation; 2000 Oct; 70(8):1188-94. PubMed ID: 11063339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis.
    Ersoy A; Kahvecioglu S; Ersoy C; Cift A; Dilek K
    Transplant Proc; 2005 Jun; 37(5):2148-50. PubMed ID: 15964363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of moderate or severe arterial hypertension with losartan.
    Dimitrova A; Todorova M; Bianov K; Halachev N; Dineva S; Elenkova A
    Folia Med (Plovdiv); 1998; 40(3B Suppl 3):43-5. PubMed ID: 10205992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study.
    Zhu X; Chen J; Han F; Cheng M; Xu L; Zhang L; Ding X; Le Y
    Transplant Proc; 2009 Nov; 41(9):3736-42. PubMed ID: 19917377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of losartan in the treatment of erythrocytosis in a young adult with CRF.
    Stoll ML; Gauthier BG; Vergara M; Ramek J; Frank R; Trachtman H
    Pediatr Nephrol; 2004 Jan; 19(1):120-1. PubMed ID: 14634866
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of losartan in renal transplant recipients.
    Hadjigavriel M; Kyriakides G
    Transplant Proc; 1999 Dec; 31(8):3300-1. PubMed ID: 10616484
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA.
    Schmidt A; Gruber U; Böhmig G; Köller E; Mayer G
    Nephrol Dial Transplant; 2001 May; 16(5):1034-7. PubMed ID: 11328912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy.
    Andersen S; Schalkwijk CG; Stehouwer CD; Parving HH
    Diabetes Care; 2000 Jul; 23(7):1031-2. PubMed ID: 10895868
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of post-transplant erythrocytosis by angiotensin II type I receptor antagonists.
    Eustace JA; Mellotte GJ; Keogn JA
    Nephrol Dial Transplant; 1996 Nov; 11(11):2373-4. PubMed ID: 8941624
    [No Abstract]   [Full Text] [Related]  

  • 36. Erythropoietin, interleukin-3, interleukin-11, and GM-CSF in posttransplant erythrocytosis treated with enalapril.
    Hu RH; Lee PH; Lee CJ
    Transplant Proc; 1996 Jun; 28(3):1545-7. PubMed ID: 8658779
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of aminophylline and enalapril in posttransplant polycythemia.
    Mazzali M; Filho GA
    Transplantation; 1998 Jun; 65(11):1461-4. PubMed ID: 9645803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fetal toxic effects and angiotensin-II-receptor antagonists.
    Martinovic J; Benachi A; Laurent N; Daikha-Dahmane F; Gubler MC
    Lancet; 2001 Jul; 358(9277):241-2. PubMed ID: 11480433
    [No Abstract]   [Full Text] [Related]  

  • 39. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade.
    Agarwal R
    Am J Physiol Renal Physiol; 2003 Apr; 284(4):F863-9. PubMed ID: 12505865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Erythrocytosis post kidney transplantation and its pharmacological treatment: angiotensin converting enzyme inhibitors or angiotensin receptor blockers in a case].
    Duclos J
    Rev Med Chil; 2000 Feb; 128(2):211-2. PubMed ID: 10962891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.